Moscow, Dec 29 (IANS/TASS) A group of Russian scientists has developed a vaccine against the deadly Ebola virus and its trials are due to be completed in February, officials said Monday.
The scientists belong to St. Petersburg's Research Institute of Influenza.
"The vaccine against Ebola created by a group of young scientists is undergoing tests for genetic stability," the official said, adding that the vaccine will be called "candidate" until its industrial production begins.
The vaccine has already been sent to the Virology Centre of the defence ministry and will be first tested on animals.
The clinical tests involving volunteers will be conducted in Africa. All the stages of the trials are due to wrap up in February, the official added.
The latest figures by the World Health Organisation (WHO) show that the toll from the current Ebola outbreak has reached 7,693 and 19,695 people have been infected.
Most deaths were reported in the hardest-hit West African countries of Liberia, Sierra Leone and Guinea.
--IANS/TASS
ksk/pku/bg
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
